Patents by Inventor Robert M. Hudziak

Robert M. Hudziak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating tumor cells by inhibiting growth factor receptor function
    Publication number: 20020192211
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Application
    Filed: June 20, 2002
    Publication date: December 19, 2002
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 6399063
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: June 4, 2002
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 6387371
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: May 14, 2002
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 6165464
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: December 26, 2000
    Assignee: Genetech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 5772997
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treatment tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: June 30, 1998
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the her2 receptor
    Patent number: 5770195
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: June 23, 1998
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 5725856
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: March 10, 1998
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 5720954
    Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: February 24, 1998
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
  • In vivo tumor detection assay
    Patent number: 5720937
    Abstract: In vivo assay methods for detecting tumors having amplified expression of the HER2 receptor are disclosed. In the assay, cells within the body of a mammal are exposed to an antibody which specifically binds to the extracellular domain of the HER2 receptor and inhibits growth in vitro of SK-BR-3 breast tumor cells which overexpress p185.sup.HER2. The antibody is generally tagged with a radioactive isotope to permit the extent of binding of the antibody to the cells to be quantified.
    Type: Grant
    Filed: November 28, 1994
    Date of Patent: February 24, 1998
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, Axel Ullrich, Brian M. Fendly
  • Monoclonal antibodies directed to the HER2 receptor
    Patent number: 5677171
    Abstract: Monoclonal antibodies which bind to the extracellular domain of the HER2 receptor and inhibit growth of SK-BR-3 breast tumor cells, which overexpress HER2, are disclosed. The monoclonal antibodies can be used for in vitro assays for detecting a tumor characterized by amplified expression of HER2.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: October 14, 1997
    Assignee: Genentech, Inc.
    Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly